Receptor mechanisms in the treatment of schizophrenia
- PMID: 15358977
- DOI: 10.1177/026988110401800303
Receptor mechanisms in the treatment of schizophrenia
Abstract
There remain many limitations to the treatment of schizophrenia. In addition to the poor response of negative and cognitive symptoms to antipsychotics, and the substantial proportion of poor- or non-responders, there are a variety of unpleasant and restricting side-effects of these drugs. The introduction of several 'atypical' drugs, with diminished propensity to cause extrapyramidal motor effects (EPS), has greatly improved the tolerability of antipsychotic treatments. The pharmacology of atypical antipsychotics is varied and, although dopamine D2 receptor antagonism is common to all antipsychotics, the mechanisms of a typicality are complex and not fully understood. Thus, antagonism at 5-HT2 and/or other receptors, weak dopamine receptor affinity and, most recently, partial agonism at dopamine D2 receptors, have been variously implicated. However, because EPS have diminished with improvements in drug treatment, drug-induced weight gain has emerged as a major concern, and the pharmacological basis of this problem, involving effects at 5-HT2c and perhaps other receptors, is yielding to investigation. Some drugs, notably the D2 partial agonists, can provide antipsychotic effects without the emergence of several of the seproblematic side-effects, which bodes well for future treatment.
Similar articles
-
Serotonin receptors: their key role in drugs to treat schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. doi: 10.1016/j.pnpbp.2003.09.010. Prog Neuropsychopharmacol Biol Psychiatry. 2003. PMID: 14642974 Review.
-
Atypical antipsychotics: mechanism of action.Can J Psychiatry. 2002 Feb;47(1):27-38. Can J Psychiatry. 2002. PMID: 11873706 Review.
-
The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.J Clin Psychiatry. 2003;64 Suppl 19:6-12. J Clin Psychiatry. 2003. PMID: 14728084 Review.
-
[New pharmacological approaches to the treatment of schizophrenia].Turk Psikiyatri Derg. 2009 Summer;20(2):175-82. Turk Psikiyatri Derg. 2009. PMID: 19504368 Review. Turkish.
-
Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.Behav Pharmacol. 2007 Mar;18(2):103-18. doi: 10.1097/FBP.0b013e3280ae6c96. Behav Pharmacol. 2007. PMID: 17351418
Cited by
-
Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.Front Pharmacol. 2022 Oct 12;13:1005702. doi: 10.3389/fphar.2022.1005702. eCollection 2022. Front Pharmacol. 2022. PMID: 36313375 Free PMC article. Review.
-
Therapeutic potential of metabotropic glutamate receptor modulators.Curr Neuropharmacol. 2012 Mar;10(1):12-48. doi: 10.2174/157015912799362805. Curr Neuropharmacol. 2012. PMID: 22942876 Free PMC article.
-
Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics.Front Behav Neurosci. 2010 Mar 18;4:8. doi: 10.3389/fnbeh.2010.00008. eCollection 2010. Front Behav Neurosci. 2010. PMID: 20305752 Free PMC article.
-
Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.J Neurosci. 2008 Oct 8;28(41):10422-33. doi: 10.1523/JNEUROSCI.1850-08.2008. J Neurosci. 2008. PMID: 18842902 Free PMC article.
-
Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/Pea-15 protein abundance.J Cell Physiol. 2012 Apr;227(4):1485-92. doi: 10.1002/jcp.22864. J Cell Physiol. 2012. PMID: 21618539 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical